M.D. Anderson Cancer Center News

OMACETAXINE MEPESUCCINATE SHOWS ACTIVITY IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE BECOME RESISTANT TO OR INTOLERANT OF PRIOR TYROSINE KINASE INHIBITORS NORTH WALES, Pa., June 1, 2012 /PRNewswire/ -- Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that ... (more)

Department of Nutritional Sciences, The University of Texas at Austin and Department of Molecular Carcinogenesis, the University of Texas MD Anderson Cancer Center, USA The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/6/S3/O11

During the last couple of weeks Todd Ackerman and I have been reporting on a controversial $20 million grant received by the University of Texas M.D. Anderson Cancer Center and Rice University.A A The story broke on May 11 when Nobel laureateA Al Gilman resigned as chief scientific officer of the Cancer Prevention and Research Institute, which has ... (more)

A Nobel laureate resigning in protest from a $3 billion cancer research initiative in Texas told colleagues in heated emails that he was trying to prevent misuse of taxpayer dollars and funding decisions based on political considerations, according to state records released Thursday.

Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

The University of Texas M.D. Anderson Cancer Center component of a $20 million grant awarded by the state cancer institute will be re-evaluated following concerns about conflicts of interest and the review process, the institute and the hospital agreed Wednesday.

Ann Chambers has a series of graphs tacked up in her office at the London Regional Cancer Program in Canada, where she is an oncologist.

In total, University of Texas institutions employ 14 of the 25 public officials on the Houston Business Journal's 2012 list of the highest-paid public officials.

For the first time in its 21-year history, M.D. Anderson Cancer Center-Orlando will welcome a new leader.

The University of Texas M.D. Anderson Cancer Center component of a controversial, taxpayer-funded $20 million grant bypassed a standard channel academia uses to prevent conflicts of interest such as nepotism, according to the Houston research hospital's second in command.

Susan G. Komen for the Cure, the largest nonprofit funder of breast cancer research outside of the U.S. Government, is announcing its funding grants to Texas breast cancer researchers, funds that total $8.4 million in new research dollars earmarked to develop breakthrough drugs for common breast cancers, more effectively treat advanced forms of the ... (more)

Until recently, we were impressed by the Cancer Prevention and Research Institute of Texas .

Two members of a state cancer review panel that gave an "enthusiastic" recommendation to fund a $20 million grant proposal from Rice University and the University of Texas M.D. Anderson Cancer Center were participants in the project.

To determine whether pol I is necessary for proliferation of normal cells, primary mouse fibroblasts were established in which Rev3L could be conditionally inactivated by Cre recombinase.

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

IsoRay, Inc., is a publicly traded US-based pharmaceutical company. The company is principally engaged in producing therapeutic medical isotopes for the treatment of prostate cancer and other malignant disease utilizing its radioisotope technology.

When City View Independent School District Superintendent Steve Harris was diagnosed with stage III squamous cell carcinoma last November, he kept his spirits up and started doing research.

It's a Thursday afternoon and Dr. Khaled Jabboury greets a patient in the waiting room of his office at the West Houston Medical Center.

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

The experimental drug ibrutinib shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia , according to interim findings from a clinical trial.